Knee osteoarthritis is the most commercially mature category of stem cell tourism — and the one where pricing claims diverge most wildly. Here's what licensed programs in China actually offer, what the published price bands mean, and how injection-based therapy compares to the surgical alternatives.
Updated August 2026. Regenerative orthopedics is the largest legitimate market for stem cell therapy in China: MSC injections into the knee are offered at licensed hospitals and in the Boao Lecheng pilot zone, and our published stem cell guide lists orthopedic regenerative protocols as a distinct, verifiable price category. But "commercially mature" doesn't mean "miracle." Here's the honest picture, with the real numbers from our published price tables.
Licensed stem cell programs in China operate under two frameworks — the same ones we document in detail for stem cell therapy for diabetes:
For knee osteoarthritis, injection-based protocols (typically MSC or MSC-derived preparations injected into the joint) are the most-studied commercial application of cell therapy in orthopedics. Published results are variable: many eligible patients report meaningful pain reduction and functional improvement lasting months to years, but no licensed program claims to "regrow cartilage to normal." The honest offer is a regulated protocol with realistic goals — less pain, better function, potentially delaying surgery — documented against a written treatment plan.
Short version: no stem cell product for knee osteoarthritis has NMPA marketing approval as of 2026 — in China or anywhere else. China's first stem cell drug authorization (January 2025, Ruibosheng / umbilical-cord MSC) is for steroid-refractory graft-versus-host disease, not osteoarthritis. What exists is a licensed clinical framework: NMPA-regulated trials and NHC-supervised investigator-initiated studies at designated Grade 3A hospitals (141 nationwide as of 2026), plus the Boao Lecheng pilot zone for international patients. Eligibility is decided by the treating team on your imaging and history — not by any clinic's marketing page.
| Eligibility factor | Typical requirement | Why it matters |
|---|---|---|
| OA grade | Moderate (Kellgren–Lawrence II–III) typical | Mild and end-stage cases are often ineligible |
| Joint stability & alignment | Stable joint, no severe malalignment | Protocols target the joint surface, not mechanics |
| Failed conservative care | Tried PT / medication / injections | Documents medical need |
| BMI / activity | Within protocol limits | Varies by protocol |
| Exclusions | Active infection, inflammatory-arthritis flare, pregnancy | Standard clinical exclusions |
Criteria above are typical published protocol ranges — final eligibility is the treating physician's call on your records. A free eligibility review is the first step.
Our published stem cell cost guide covers orthopedic regenerative protocols as a distinct category, so the China figures below are real published bands from our network, escrowed all-in — no condition-specific markup has been invented here:
| Program | Typical all-in range | What's included |
|---|---|---|
| Knee OA regenerative protocol (MSC injection course) | $10,000–22,000 per course — orthopedic regenerative band from our published guide; exact protocol pricing for knee OA [TO-VERIFY] | Hospital, physician, cell product, injections, nursing, room, translation, coordination |
| MSC IV + exosome combo protocols | $12,000–28,000 per course | Hospital, physician, cell product, nursing, room, translation, coordination |
| Eligibility workup (pre-travel) | $800–2,000 | Records review, imaging review, remote physician consult |
| Follow-up program (12 months) | $2,000–5,000 | Remote monitoring, telehealth consults, lab coordination |
Compare: the same category of regenerative orthopedic protocol runs $30,000–70,000 per course in the US (published in our stem cell guide) — China is typically ~65% less. And if your joint is beyond injection therapy, our knee replacement guide publishes surgical pricing: total knee replacement at $8,000–15,000 all-in in China versus $30,000–50,000+ in the US. The point of publishing both: you should choose the right treatment, not the cheapest price.
We only publish price tables for programs we've verified directly. Our own China figures below come from our published stem cell guide; foreign-market figures for knee osteoarthritis specifically are not published on this site, so we've marked them [TO-VERIFY] rather than invent numbers. Verify any figure with the provider before committing.
| Market / program | Typical range (USD) | Regulatory status |
|---|---|---|
| China — Boao Lecheng / orthopedic network programs | $10,000–22,000 per course (published orthopedic regenerative band); knee OA-specific quote [TO-VERIFY] | Licensed pilot-zone or Grade 3A hospital protocols, escrowed payment |
| China — other broker listings (Boao) | $15,000–35,000 (published broker-listing range) | Same zone — verify hospital and protocol before comparing prices |
| United States | $30,000–70,000 per regenerative course (published in our stem cell guide); knee OA-specific [TO-VERIFY] | FDA has approved no MSC therapy for knee osteoarthritis as of 2026 |
| Switzerland / Germany | [TO-VERIFY] — not published on this site | Varies; some clinics operate under compassionate-use rules |
| Mexico (Tijuana / Monterrey) | [TO-VERIFY] — not published on this site | Largely unregulated; no mandatory outcome tracking |
| Thailand | [TO-VERIFY] — not published on this site | Semi-regulated; oversight varies by hospital |
Why the table reads this way: our published guides cover China's licensed programs directly, and we refuse to quote foreign-market prices we haven't verified. The China numbers above are real published bands from our network; anything marked [TO-VERIFY] gets verified — with the provider, in writing — before you commit. Treat any sub-$10,000 quote for an injection course as a cue to verify the hospital and protocol, not as a deal.
China's Hainan Free Trade Port and the Boao Lecheng International Medical Tourism Pilot Zone are the government-designated venue for advanced licensed therapies, and our orthopedic network includes designated centers such as Beijing Jishuitan Hospital, Shanghai Sixth People's Hospital, and West China Hospital (Chengdu). Key facts we've published:
Our escrow structure is the same one documented across this site — and it matters for orthopedics because injection courses are sold in packages, which is exactly where vague "package deals" hide:
No — as of 2026 no stem cell product for knee osteoarthritis has NMPA marketing approval anywhere, including China. Treatment happens under licensed trial or pilot-zone frameworks. Anyone claiming an "NMPA-approved knee osteoarthritis stem cell treatment" is misstating the regulatory status.
No licensed program guarantees avoiding surgery. For eligible patients with moderate osteoarthritis, injection-based protocols may meaningfully reduce pain and delay the need for replacement — but outcomes vary. We publish knee replacement pricing side by side so you can compare both paths with your physician.
Typically 2–4 weeks for the initial program, depending on the protocol. Follow-up is remote for up to 12 months.
If you meet inclusion criteria — OA grade, age and organ-function limits — trial enrollment can reduce or waive treatment cost, but you bear travel and stay costs and must meet strict criteria. We can walk through both paths in your free review.
Describe your case and current treatment. We'll respond within one business day.
💬 Get your estimate on WhatsApp — usually replies within minutes